CD8A and cancer: It is well-known that neoantigens accumulating on tumor cells are initially recognized and presented by dendritic cells, subsequently promoting the production of CD8+ T cells, which are considered the main executors of cancer destruction, enhancing immune cell activities in the microenvironment, and thus preventing the development of cancer (Chen and Flies, 2013; Buoncervello et al., 2019).